WISE SPA

Their core work

WISE SPA is an Italian medical device company developing a minimally invasive spinal cord stimulation (SCS) lead specifically designed for chronic pain management. Their core innovation — the PercPad — is a percutaneously implantable paddle lead, meaning surgeons can deliver a paddle-style electrode array through a needle rather than performing open back surgery. This addresses a major clinical tradeoff in neuromodulation: paddle leads provide superior stimulation coverage compared to cylindrical leads, but traditionally required invasive surgery to implant. WISE SPA's technology aims to give patients the benefits of paddle-lead SCS with the recovery profile of a minimally invasive procedure.

What they specialise in

How they've shifted over time

WISE SPA's H2020 participation spans a single, focused product development trajectory rather than a broad research agenda. The Phase 1 feasibility project in 2019 established the concept without detailed keyword tagging — indicating an early-stage proof-of-concept moment. By Phase 2 (2020–2022), the focus crystallized around flexible electrodes, neuromodulation, and minimally invasive surgery, showing that the company moved from concept validation to engineering execution. There is no evidence of pivoting or diversification — this is a company that defined its bet early and doubled down.

WISE SPA is on a product commercialization trajectory — having completed the full SME Instrument Phase 1 → Phase 2 pathway, they are likely post-development and moving toward regulatory approval and market entry for the PercPad device.

How they like to work

WISE SPA has operated exclusively as a project coordinator and, notably, appears to have run both PercPad projects without consortium partners — consistent with the SME Instrument structure, which funds individual companies directly. This means they are self-contained in their R&D execution and do not have an established track record of large consortium collaboration. Any future partner would be entering a relationship with a company accustomed to running its own show, which can mean fast decisions but less experience navigating multi-partner dynamics.

With zero recorded consortium partners and zero countries collaborated with under H2020, WISE SPA has no visible EU research network to speak of — their projects were self-directed single-beneficiary grants. Their relationships likely exist in clinical and commercial channels (hospitals, pain clinics, device distributors) rather than in the academic consortium world.

What sets them apart

WISE SPA occupies a very specific niche: the gap between the clinical superiority of paddle-lead SCS and the patient and surgeon preference for minimally invasive procedures. This is a real, commercially validated pain point in the neuromodulation industry, where major players like Medtronic and Abbott have not yet solved percutaneous paddle delivery at scale. A company that can crack this problem with flexible electrode technology would have a defensible position in a multi-billion euro chronic pain device market. Their unique value is not broad research capability but deep, focused product engineering on a single high-stakes clinical problem.

Highlights from their portfolio

• PercPad
  The SME-2 phase (€2.318M, 2020–2022) represents one of the larger single-company SME Instrument awards and marks the full development phase of a potentially disruptive implantable neuromodulation device.
• PercPad
  The SME-1 feasibility study (2019) demonstrates a successful Phase 1 → Phase 2 SME Instrument progression, confirming that the PercPad concept passed independent European Commission evaluation before receiving major development funding.